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Abstract The modulation of urokinase plasminogen activator receptor (uPAR) gene expression by tumor necrosis factor alpha (TNF~), phorbol 
ester (PMA) and amiloride was studied in three colon cancer cell lines, uPAR mRNA and protein were induced by TNF~ and by PMA but were 
inhibited by amiloride at concentrations of 0.1 to 1 mM in the presence or absence of TNFc~ and PMA. Nuclear un-on transcription assay indicated 
that the effects of amiloride and TNF~ were mediated at least in part at the transcriptional level, whereas PMA may act in part via a post- 
transcriptional mechanism. These results suggested that uPAR gene expression is modulated by multiple signal transduction pathways. 
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1. Introduction 
Activation of receptor-bound prourokinase (pro-uPA) on 
the cell surface appears to play an important role in some 
biological processes including cancer cell invasion and metasta- 
sis, monocyte migration, angiogenesis, wound healing and tro- 
phoblast implantation [1]. The urokinase plasminogen activa- 
tor receptor (uPAR) specifically recognizes high molecular 
weight pro-uPA and active uPA by their epidermal growth 
factor (EGF)-like terminal domains. Receptor-bound uPA cat- 
alyzes the formation of plasmin on the cell surface to generate 
the proteolytic ascade that contributes to the breakdown of 
basement membranes and extracellular matrix [2]. uPAR is a 
55-60 kDa glycoprotein that attaches to plasma membranes by 
glycosyl-phosphatidyl-inositol (GPI) linkage [3]. The 1.4 kb 
uPAR gene has been cloned [4] and mapped to chromosome 
19q13.2 [5,6]. uPAR is expressed in human colon 
adenocarcinoma cells at the invasive front [7] and in tumor- 
associated macrophages in human breast carcinoma [8]. Block- 
ade of uPAR on human PC3 prostate carcinoma cells by inac- 
tive uPA markedly inhibited metastatic activity in a nude 
mouse model [9]. There is increasing evidence that uPAR ex- 
pression on the surface of adenocarcinoma cells is central to the 
invasion process and that receptor-bound uPA is the preferred 
site for mediating proteolysis. The regulation of the uPAR gene 
therefore may be a pivotal point in the control of the malignant 
behavior of a colon cancer cell. 
The uPAR protein is inducible in monocytes by the tumor 
promoter, phorbol myristate acetate (PMA) [10] and by the 
cytokines, interferon gamma (IFN-y) and tumor necrosis fac- 
tor alpha (TNFc 0 [11]. uPAR biosynthesis, the uPAR mRNA 
level and gene transcription are also increased by transforming 
growth factor beta (TGFfl) and dexamethasone in A549 lung 
carcinoma cells [12], but reports of transcriptional regulation 
of uPAR mRNA expression by TNF~ in any cell type are 
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lacking. The question of negative regulation of uPAR gene 
expression also remains unexplored. 
Amiloride is a specific and an effective inhibitor of sodium 
channels in epithelial cell transport systems [13]. It inhibits 
tumor growth [14] and metastasis [15], and may represent a
prototype for potential anticancer drugs because it also inter- 
feres with the regulation of intracellular pH [16]. Although 
amiloride competitively inhibits the catalytic activity of uPA 
[17], little is known concerning the potential role of amiloride 
in the regulation of uPA receptor mRNA and its protein. In this 
paper the positive modulation of uPAR mRNA and protein by 
TNFc~, PMA and cycloheximide and the negative regulatory 
effects by amiloride on uPAR gene expression in human colon 
cancer cells are reported. 
2. Materials and methods 
2.1. Materials 
Human urokinase (Actisolv, high Mr) was a gift from Dr. E. Schuler, 
Behringwerke, Marburg, Germany and recombinant human TNF~ 
(activity: 1 unit ~0.0455 ng) was provided by the Asahi Chemical Com- 
pany, Tokyo, Japan. PMA, CHX and amiloride were from Sigma 
Chem. Co., St. Louis, USA. 
2.2. Cell culture 
The human colon cancer cell lines, HCT116 [18], KM12SM [19] and 
LM1215 [20], have been described previously. The HCT116 cells were 
obtained from the American Type Tissue Collection. The KM12SM 
cells were a gift from Dr. I.J. Fidler, M.D. Anderson Cancer Center, 
University of Texas, Houston, USA and the LIM1215 cells were pro- 
vided by Dr. R.T. Whitehead, Ludwig Institute for Cancer Research, 
Melbourne, Australia. All cell lines stained negative for Mycoplasma 
contamination using Hoechst stain 33258. Cells were maintained in
RPMI-1640 medium supplemented with 10% fetal calf serum (FCS). 
Before stimulation, cells were washed three times with PBS and incu- 
bated overnight or for 4 h in RPMI serum-free media. Stimulants were 
added to cells at a density of about 1 x 10 6 cells per ml. Immediately 
before harvest, cell viability was consistently found to be > 90%. 
2.3. RNA preparation and Northern blot analysis 
RNA was purified from stimulated or unstimulated cells using the 
guanidinium isothiocyanate method [21]. RNA samples were electro- 
phoresed on 1% formaldehyde-containing agarose gels, transferred to 
a nitrocellulose membrane and further processed. Hybridization was 
carried out in 50% (vol/vol) formamide/6 x SSC/5 x Denhardt's solu- 
tion/2% Sarcosyl/200 #g/ml salmon sperm DNA. The membranes were 
exposed to Kodak XAR film at -70°C using intensifying screens and 
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multiple film exposure times were used to ensure linearity of band 
intensities. The intensities ofmRNA bands in the autoradiographs were 
scanned and quantitated by a video densitometer (Model 620, Bio- 
Rad). mRNA intensities are calculated relative to the intensity of the 
18 S rRNA internal control. The RNA molecular markers used were 
purchased from Promega corporation. 
2.4. cDNA probes 
The 1.144 kb human uPAR cDNA [4] used was a gift from Dr. 
E.K.O. Kruithof, Lausanne, Switzerland. Human 18S ribosomal DNA 
(18S rDNA) [22] was a gift from Dr. B.E.H. Maden, University of 
Liverpool, UK. Human fl-actin cDNA [23] was a gift from Dr. H.D. 
Campbell, The Australian National University. Human ubiquitin 
cDNA [24] was a gift from Dr. R,T. Baker, The Australian National 
University. cDNA probes were labelled with [~-32p]dCTP by the ran- 
dom priming method [21]. 
2.5. Nuclear un-on transcription assay 
Nuclei were isolated from HCT116 cells treated with TNFct, PMA 
or amiloride, according to the method previously described [25,26]. In 
brief, about 5 × 10 7 cells were washed in buffer (10 mM "Iris, pH 7.5/2 
mM MgCIJ3 mM CaC12t3 mM dithiothreitol/0.3 M sucrose). Nuclei 
were then pelleted after lysis of the cells in the same buffer containing 
0.1% Triton X-100. For the transcription elongation reaction, freshly 
prepared nuclei were incubated at 30°C for 30 min with [~-32p]UTP, 
and run-on analysis performed (26), In a given experiment, each filter 
was hybridized to DNA immobilized on nitrocellulose with the same 
amount of 32P-labelled RNA. The filters were then exposed at -70°C 
to Kodak XAR film for 7-14 days using intensifying screens. The 
intensities of mRNA bands in the autoradiographs were scanned and 
quantitated by a video densitometer (Model 620, Bio-Rad). mRNA 
intensities are calculated relative to the intensity of the fl-actin internal 
control. 
2.6. uPAR protein assay 
Cells were rinsed and maintained overnight in serum-free media in 
the presence or absence of stimulants. The cells were then rinsed with 
acidic glycine buffer (50 mM glycine-HCl, pH 3.0, 0.1 M NaC1), washed 
twice with binding buffer (RPMI containing 0.1% BSA and 20 mM 
HEPES pH 7.4), and incubated with a range of concentrations of 
[~25I]uPA in binding buffer for 45 rain at room temperature [27]. To 
determine non-specific binding, 50-fold higher concentrations of unla- 
belled uPA were added to the incubate. Unbound uPA was removed 
and the radioactivity of the cell lysates measured by gamma counter. 
Scatchard analysis was used to calculate the dissociation constant value 
and the average number of the uPAR on the cell surface [28]. The 
statistical significance of the differences between uPAR protein assays 
was analyzed by a Student's t-test. 
3. Results 
3.1. Induction of uPAR mRNA accumulation by TNFct, PMA 
and cycloheximide (CHX) 
To determine whether uPAR mRNA is induced by TNFct, 
PMA or CHX in colon cancer cells, RNA was isolated from 
cells treated with stimili and analyzed by Northern blotting. 
Unstimulated HCT116 cells expressed very low levels of 1.4 kb 
uPAR transcripts. After TNFct stimulation however, there 
were marked increases in the levels of uPAR mRNA which 
appeared at about 1 h, peaked at 2 h and declined at 6 h (Fig. 
1A). uPAR mRNA was increased in a dose-dependent manner 
at TNF~ concentrations of 2.2-2,200 units/ml (Fig. 1B). After 
PMA stimulation, uPAR mRNA was increased at 2 h and high 
levels were sustained for 24 h in HCT116 cells (data not shown). 
Similar TNFc~ or PMA effects on uPAR mRNA were found 
in the two other colon cancer lines, KM12SM and LIM1215 
(Fig. 3). 
To investigate whether induction of uPAR gene expression 
by TNF~ or PMA was dependent on de novo protein synthesis, 
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Fig. 1. Time- and dose-dependent induction of uPAR mRNA accumu- 
lation by TNF~ in HCT116 cells. The same Northern blot was hybrid- 
ized to 32p-labelled uPAR cDNA and 18S rDNA probes as indicated. 
(A) Time course of uPAR mRNA accumulation i duced by TNF~ 
(2,000 units/ml). Autoradiographic exposure times were 12h (for uPAR 
as probe) and 8h (for 18S rDNA as probe). Lane 1, untreated; lanes 24,  
TNFct for 1, 2 and 6 h. (B) Dose-dependent induction of uPAR mRNA 
accumulation in cells induced by TNF~ for 4h at the concentrations of 
0, 2.2, 22, 220 and 2,200 units/ml (lanes 1, 2, 3, 4 and 5, respectively). 
Autoradiographic exposure times were 48h (for uPAR as probe) and 
18 h (for 18S rDNA as probe). Each experiment was repeated at least 
two times and representative data shown in the figures. 
CHX was used to inhibit protein synthesis. Cells were preincu- 
bated with CHX (20 gtg/ml) for 30 min to ensure inhibition of 
protein synthesis at an early time point and then TNF~ or PMA 
was added for 4 h. Northern blot analysis showed that in 
HCT116 cells, CHX alone induced uPA mRNA suggesting that 
the uPAR gene is regulated by a labile repressor protein (Fig. 
2B, lane 4) [29]. uPAR mRNA was also induced by CHX in 
HCT116 cells stimulated by TNFct or PMA (data not shown), 
suggesting that stimulation of uPAR does not need de novo 
protein synthesis. As expected, synthesis of uPAR protein was 
totally inhibited by CHX addition (data not shown). No signif- 
icant difference was observed in 18S rRNA, which served as a 
control. 
3.2. Inhibition of uPAR mRNA by amiloride 
As amiloride competitively inhibits the catalytic activity of 
uPA it was of interest o determine whether it also affects the 
synthesis of the uPA receptor. When concentrations of amilo- 
ride (0.001-1 mM) known to inhibit the Na÷/Ca 2+ exchanger, 
the Na+,K÷-ATPase and Na÷-coupted solute transport [30] 
were added in the presence of PMA to HCT116 cells, there was 
a dose-dependent inhibition of 55% and 80% of the uPAR 
mRNA level at concentrations of 0.1 mM and 1 mM, respec- 
tively, as determined by scanning densitometry (Fig. 2A, lanes 
5,6). Inhibition was detected whether amiloride was added si- 
multaneously with PMA (Fig. 2A, lanes 5,6), 2 h after PMA 
(lane 7) or 1 h before PMA (lane 8). Reductions of 41% of 
uPAR mRNA levels occurred in HCT l l6  cells treated with 
amiloride alone at a concentration of 1 mM (Fig. 2B, lane 3) 
but no inhibition of uPAR mRNA was detected at 0.1 mM 
(Fig. 2B, lane 2). Amiloride (1 mM) also markedly inhibited the 
uPAR mRNA expression induced by CHX (Fig. 2B, lanes 4,5) 
and TNF~ (Fig. 2B, lanes 6,7). Similar effects of amiloride 
inhibition were found in the other colon cancer cell lines, 
KM12SM and LIMI215 (Fig. 3). Levels of 18S rRNA in these 
cell lines were not significantly affected by exposure to amilo- 
ride. 
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Fig. 2. Effect of amiloride on uPAR mRNA accumulation i HCT116 cells. Cells were treated for 4 h with PMA (50 ng/ml), CHX (20/tg/ml) or 
TNFc~ (220 units/ml) in the presence or absence of amiloride. The same Northern blot was hybridized to 32p-labelled uPAR cDNA and 18S rDNA 
probes as indicated. (A) Dose-dependent i hibition of uPAR mRNA accumulation by amiloride. Autoradiographic exposure times were 24 h (for 
uPAR cDNA as probe) and 6 h (for 18S rDNA as probe). Lane 1, untreated; lanes 2-6, PMA plus amiloride at 0, 0.001, 0.01, 0.1, and 1 mM, 
respectively; lane 7, PMA-treated for 2 h then amiloride (lmM) added; lane 8, amiloride (1 mM)-treated for lh then PMA added for 3 h. (B) Effect 
of amiloride on uPAR mRNA accumulation. Autoradiographic exposure times were 91 h (for uPAR cDNA as probe) and 5 h (for 18S rDNA as 
probe). Lane 1, untreated; lane 2, amiloride (0.1 mM); lane 3, amiloride (1 mM); lane 4, CHX; lane 5, CHX plus amiloride (1 mM); lane 6, TNF~; 
lane 7, TNFct plus amiloride (1 mM). The corresponding densitometry esults are shown underneath. Each experiment was repeated at least three 
times and representative data shown in the figures. 
3.3. Effects of PMA, TNFct or amiloride on uPAR transcription 
in isolated nuclei 
Incorporation of label via elongation of nascent uPAR tran- 
scripts in isolated nuclei was used as a measure of the level of 
uPAR gene transcription in HCT116 cells. The radiolabelled 
transcripts were then hybridized with uPAR cDNA bound to 
nitrocellulose in order to detect uPAR mRNA.  The results of 
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Fig. 3. Effect of amiloride (1 mM) on uPAR mRNA accumulation i
KM12SM (A) and LIM1215 (B) cells. Cells were treated for 4 h with 
PMA (50 ng/ml) or TNFct (220 units/ml) in the presence or absence of 
amiloride (1 mM). Autoradiographic exposure times were 72 h (A) and 
70 h (B). Lane 1, untreated; lane 2, PMA; lane 3, PMA plus amiloride; 
lane 4, TNFot; lane 5, TNF~ plus amiloride. Each experiment was 
repeated at least three times and representative data shown in the 
figures. 
these nuclear run-on transcription assays are shown in Fig. 4. 
uPAR transcripts were expressed in nuclei from unstimulated 
HCT116 cells but were markedly reduced in the cells that had 
been treated with amiloride (Fig. 4A). uPAR mRNA,  however, 
was increased in the cells exposed to TNF~ (Fig. 4B), but not 
PMA (Fig. 4C), as determined by scanning densitometry. These 
assays indicate that the effect of amiloride and TNF~, but not 
PMA, is mediated, at least in part, at the level of transcription. 
3.4. Effects of PMA, TNFot and amiloride on cell surface uPAR 
protein levels 
As shown in Fig. 5, the level of uPAR protein on the surface 
of unstimulated (control) HCT116 cells was 4.2 + 0.13 ng per 
106 cells (row 1). After stimulation by PMA, cell surface uPAR 
protein levels increased about 1.6-fold (row 3) while TNF~ 
treatment induced less levels of uPAR protein production (row 
5). After treatment with amiloride alone, a 52% reduction of 
uPAR protein levels was observed (rows 1 and 2). Amiloride 
also markedly decreased the levels of PMA-induced (rows 3 
and 4) or TNF~-induced uPAR protein (rows 5 and 6). These 
effects were statistically significant (P < 0.05). Similar effects of 
PMA, TNF~ and amiloride on cell surface uPAR protein levels 
were found in the other colon cancer cell lines, KM12SM and 
LIM1215 (data not shown), uPAR protein levels on the cell 
surface, therefore reflected PMA and TNFct induction and 
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Fig. 4. Nuclear un-on transcription a alysis of effects of TNF~t, PMA 
and amiloride on uPAR gene transcription i HCT116 cells. Nuclei 
were isolated from HCT116 cells treated with amiloride (1 mM/mi) (A), 
TNF~ (2,000 units/ml) (B), PMA (30 ng/ml) (C). Following in vitro 
transcription, RNA was purified from the nuclei and hybridized with 
uPAR cDNA, fl-actin cDNA or vector DNA (pGEM-1 and pBluscript 
SK) immobilized on nitrocellulose filters. Hybridized 32p-labeled nu- 
clear RNA was detected by autoradiography. Autoradiographic expo- 
sure time was 6 days for experiments (A) and (B), and 10 days for 
experiments (C). Each experiment was repeated at least wice and rep- 
resentative data shown in the figures. 
amiloride inhibition, of uPAR mRNA levels in colon cancer 
cells. 
4. Discussion 
This paper reports the negative ffect of amiloride and the 
positive effects of TNFct and PMA on uPAR expression in 
colon cancer cell lines. Transcriptional e ongation experiments 
suggested that the suppression effect of amiloride and the in- 
duction effect of TNFct were mediated, at least in part, at the 
level of transcription. The induction effect of PMA, however, 
may be mediated at the level of post-transcription. 
TNF~ has a wide range of biological activities affecting the 
growth, differentiation and functions of many cell types [31]. 
Amongst its protean biological functions, TNFct induces rapid 
expression of the uPA gene in pulmonary epithelial cells [32]. 
The results reported here indicate that treatment with TNFct 
also increases levels of uPAR mRNA and protein expression 
in colon carcinoma cells. In this context, it has been reported 
that a small proportion of infiltrating macrophages, but not 
colon cancer cells, expresses TNFct mRNA and protein in 
colon cancer tissue [33], suggesting that the tumor microenvi- 
ronment may modulate uPA and uPAR expression in colonic 
cancers thereby influencing tumor invasiveness. 
Amiloride is a specific inhibitor of sodium channels in many 
epithelial transport systems. It is also a competitive inhibitor 
of uPA [17] and its receptor, but not tissue plasminogen activa- 
tor (tPA), plasmin, plasma kallikrein or thrombin, indicating 
that it does not exert a general inhibitory action on cell metab- 
olism. This paper reports that amiloride markedly inhibits 
uPAR mRNA induction in colon cancer cell lines. We found 
that amiloride had no measurable effects on cell viability or on 
the yield of the total RNA. When the uPAR probe was eluted 
from the filters and the same RNA blot was then hybridized 
using 32p-labelled human fl-actin [23], ubiquitin cDNA [24] or 
18S rRNA, no significant changes in the fl-actin and ubiquitin 
mRNAs (data not shown) or 18S rRNA were detected regard- 
less of whether the cells had been exposed to amiloride. This 
result shows that amiloride may be selective in inhibiting ene 
expression. There is evidence that amiloride given to rats in 
their drinking water completely prevented pulmonary metasta- 
sis when rat mammary adenocarcinoma cells were injected in- 
travenously [15]. This observation combined with the inhibitory 
effects of amiloride on uPAR expression reported in this paper, 
encourage further research into the mechanisms of amiloride- 
induced inhibition of metastasis that may offer fresh insights 
into the prevention of invasion and metastasis by 
adenocarcinomas. 
This paper suggests that uPAR gene expression may be mod- 
ulated by multiple pathways of signal transduction i  colon 
cancer cells. These signalling pathways may include the well- 
characterized protein kinase C/cAMP-dependent pathways, 
and other less-well understood pathways uch as those involv- 
ing the TNFct receptor and, as described here, the amiloride- 
sensitive Na ÷ channel. PMA activates protein kinase C which 
can phosphorylate and modulate many proteins [34]. PMA has 
been shown to affect ranscription of numerous genes, increas- 
ing transcription of many cytokine genes [35], and inhibiting 
phosphoenolpyruvate carboxykinase g ne activity [36]. The re- 
suits of the transcriptional e ongation assays reported in this 
paper suggest that PMA stimulation may lead to stabilization 
of uPAR mRNA in colon cancer cells. This is also true in the 
case of GM-CSF gene expression in cells treated with PMA 
[37]. Human TNF~, however, is reported to regulate gene ex- 
pression in eukaryotic ells by binding to the TNFct receptors 
[38]. The nuclear un-on transcription assay suggested that the 
effect of TNFct was mediated at the transcriptional level and 
may be mediated through the transcriptional factor NF-kB 
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Fig. 5. Effects of PMA, TNF~ and amiloride on uPAR protein produc- 
tion in HCT116 cells measured by the [125I]uPA binding assay. Cells 
were treated with PMA (50 ng/ml) or TNF~ (440 units/ml) in the 
presence or absence of amiloride (1 mM) for 12 h. Columns, means of 
three separate xperiments; bars, S.D. Statistical evaluation showed 
that the effects of PMA, TNFct and amiloride in uPA binding in 
HCT116 cells were significant (P < 0.05). 
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which is activated by the sphingomyelin pathway in HL-60 cells 
[39]. The experiments reported here also show that amiloride 
downregulates uPAR mRNA at the level of transcription in 
colon cancer cells suggesting that the Na + channel may be 
involved in the regulation of the uPAR gene. Although the 
mechanism in the regulation of genes by amiloride is unclear, 
recent reports indicate that amiloride is able to bind to diamine 
oxidase, an amiloride binding protein, that is very similar to the 
Na + channel and to catalyze the degradation of compounds 
including putrescine and histamine [40]. To characterize the 
signal transduction pathways which regulate the uPAR gene, 
further experiments are currently in progress to study the sig- 
nalling pathways and the regulatory sequence(s) and trans- 
acting factor(s) that contribute to regulation of uPAR gene 
expression by PMA, TNFct and amiloride. 
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